{"entity":{"id":"nct06801002","kind":"trial","name":"Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies","aka":[],"tldr":"A phase 1 trial of JBZ-001 run by Jabez Bioscience, Inc, now recruiting.","summary":"Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies is a phase 1 interventional study registered as NCT06801002 by Jabez Bioscience, Inc, with 25 participants planned, started 2025-03-17. Conditions recorded: Solid Tumor. Interventions recorded: JBZ-001.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06801002","url":"https://clinicaltrials.gov/study/NCT06801002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["jbz-001"],"companies":["jabez-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06801002","phase":"1","setting":"A Phase 1, Open-label, Dose-escalation and Expansion, First-in-human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JBZ-001, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Patients With Advanced Solid and Hematological Malignancies","sponsor":"Jabez Bioscience, Inc","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06801002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"jbz-001","kind":"drug","name":"JBZ-001","route":"/drugs/jbz-001/"}],"company":[{"id":"jabez-biosciences","kind":"company","name":"Jabez Biosciences","route":"/companies/jabez-biosciences/"}]}}